Out of 10,000 compounds that are discovered and developed, only 1 makes it to the market. The  “Siosomes^® Technology ” allows for the delivery and targeting of small and large molecules, monoclonal antibodies, enzymes, proteins, vaccines, vitamins  and inhalations through different routes of administration which would offer greater advantages for the use of your drugs (increase of drug bioavailability, sustained release, lower therapeutic dose, less toxicity and increase solubility).

Siosomes^® can be manufactured in different sizes, dependant on use and requirements of clients, ranging from 40nm – 1500nm in size with +/- 10% distribution.

Currently, SIOGEN has developed around 30 different Siosomes^® constructs each with specific inherent characteristics, including anti-viral, anti-bacterial, anti-fungal, and anti-cancer. Siosomes^® can be developed to precisely address issues such as toxicity, targeting, solubility, immunogenicity, bioavailability, and efficacy. Additionally, it is possible to construct multi-lamellar (layered) Siosomes^® for sustained release (longer half life) of drugs and pro-drugs.

The outer structure of the Siosomes^® can be modified to improve their characteristics and targeting unlike liposomes; for example PEGylation for immuno-avoidance; the addition of The technology can be used for all forms or mode of administration be it oral, transdermal, inhalation, gel, intravenous and intramuscular as well. Through Siosomes^®, new IPs can be created thus providing life cycle extensions for existing drugs and LCM.

For certain transmembrane proteins, entrapment – where the target drug is held between two outer layers of the Siosomes^® - creates a stable carrier for the protein. Other molecules, with toxicity issues for example, can be fully encapsulated – held in the centre core of the Siosomes^® and released at the drug target – to prevent side effects.

The following are some key points about SIOGEN.

• SIOGEN has conducted extensive preclinical validation both in vitro and in vivo studies (over 12 years of solid R&D), including 19 post graduate theses and 15 peer reviewed publications, to generate a comprehensive data package establishing its breakthrough platform drug delivery technology (Siosomes^®).
  
  
• SIOGEN’s business model is to partner its technology for the development of drugs, vaccines, cosmetics and herbal in exchange for upfront license fees, milestones, and royalties. Existing partners include pharmaceutical companies, a US based animal health company, the Malaysian Government, and University Science Malaysia. We are also in the final discussion with several middle sized biopharmaceutical companies as well.
  
  
• The core Siosomes^® technology is protected through 7 patent families; further IP can be generated in collaboration with partners through reformulation of existing, off-patent and formulation of novel drugs, and manufacturing processes.
  
  
• For R&D purposes Siosomes^® can be manufactured within SIOGEN’s GMP facilities in Germany. For commercial scale production, Siosomes^® production can be easily integrated in the customers’ existing manufacturing process.

If you want to share in our success contact Dr Shermal Perera shermal@siogen.com or Mr Thayalan Arumugam thayalan@siogen.com